Cellectar Biosciences Inc. (CLRB) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cellectar Biosciences Inc... (CLRB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.27

-0.01 (-4.19%)

At close: Jan 14, 2025, 3:59 PM

0.26

-3.63%

Pre-market Jan 15, 2025, 06:32 AM EST

undefined% (undefined)

Bid	0.26
Market Cap	11.15M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.41
PE Ratio (ttm)	-0.19
Forward PE	n/a
Analyst	Hold

Ask	0.27
Volume	2,018,356
Avg. Volume (20D)	2,305,949
Open	0.28
Previous Close	0.28
Day's Range	0.25 - 0.29
52-Week Range	0.22 - 4.45
Beta	undefined

About CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients;...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 10, 2005

Employees 20

Stock Exchange NASDAQ

Ticker Symbol CLRB

Website https://www.cellectar.com

Analyst Forecast

According to 2 analyst ratings, the average rating for CLRB stock is "Hold." The 12-month stock price forecast is $28, which is an increase of 10266.53% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

-76.16%

Cellectar Biosciences shares are trading lower aft... Unlock content with Pro Subscription

5 months ago · Source

-18.54%

Cellectar Biosciences shares are trading lower. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.

News

2 weeks ago · finbold.com

Wall Street's top 5 stocks with the biggest upside in 2025

As 2024 is nearing its end, investors with a time machine are looking to visit December 2023 and take their long positions in Nvidia (NASDAQ: NVDA), Tesla (NASDAQ: TSLA), Super Micro Computer (NASDAQ:...

1 month ago · benzinga.com

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

On Tuesday, Cellectar Biosciences, Inc. CLRB unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets cancer.

1 month ago · seekingalpha.com

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2024 Earnings Conference Call November 18, 2024 8:30 AM ET Company Participants Anne Marie Fields - Managing Director, Precision AQ Jim Caruso - President...